{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:26:21Z","timestamp":1790040381274,"version":"4.0.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement (CNS B-ALL) have poor outcomes and were frequently excluded from CD19-targeting chimeric antigen receptor (CAR) T-cell clinical trials. The efficacy and safety of brexucabtagene autoleucel (brexu-cel) in adults with R\/R B-ALL was established by the ZUMA-3 trial, which excluded patients with advanced or symptomatic CNS involvement. In this retrospective multicenter analysis, we investigated the safety and efficacy of brexu-cel in patients with CNS B-ALL using data from the ROCCA (Real-World Outcomes Collaborative for CAR T in ALL) consortium. Of 189 patients who received infusion, 31 had CNS-2 (presence of blasts in cerebrospinal fluid with &amp;lt;5 white blood cells [WBCs] per \u03bcL) or CNS-3 (presence of blasts with &amp;gt;5 WBCs per \u03bcL and\/or clinical signs\/symptoms) disease before apheresis and are the focus of this report. The median age was 46.5 years (range, 24-76), and 58.1% were male. Most (87.1%) received bridging therapy. After brexu-cel, 21 of 24 patients with CNS restaging (87.5%) achieved CNS-1. Additionally, 28 of 30 evaluable patients achieved marrow complete remission; 25 were measurable residual disease negative. No statistically significant differences were seen in progression-free survival or overall survival after brexu-cel among patients with or without CNS involvement. Similarly, grade 3\/4 immune effector cell\u2013associated neurotoxicity syndrome occurred similarly in patients with (35.5%) and without (30%) CNS disease. In conclusion, our data suggest that brexu-cel results in high response rates in patients with CNS B-ALL, with toxicity comparable with that in patients without CNS involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015779","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T14:33:19Z","timestamp":1746628399000},"page":"4081-4089","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia with CNS involvement"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2532","authenticated-orcid":false,"given":"Ibrahim N.","family":"Muhsen","sequence":"first","affiliation":[{"name":"1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-5152","authenticated-orcid":false,"given":"Gregory W.","family":"Roloff","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Valtis","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam E.","family":"Kopmar","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center and University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone E.","family":"Dekker","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center and University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-0623","authenticated-orcid":false,"given":"Matthew","family":"Connor","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mercadal","sequence":"additional","affiliation":[{"name":"8Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-1755","authenticated-orcid":false,"given":"Kaitlyn C.","family":"Dykes","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-4434","authenticated-orcid":false,"given":"Nikeshan","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhang","sequence":"additional","affiliation":[{"name":"12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Miller","sequence":"additional","affiliation":[{"name":"12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Guzowski","sequence":"additional","affiliation":[{"name":"13Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"14Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet","family":"Majhail","sequence":"additional","affiliation":[{"name":"15Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Battiwalla","sequence":"additional","affiliation":[{"name":"15Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem M.","family":"Solh","sequence":"additional","affiliation":[{"name":"13Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz A.","family":"Malik","sequence":"additional","affiliation":[{"name":"16Center for Blood Cancer and Oncology, Texas Transplant Institute, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mathews","sequence":"additional","affiliation":[{"name":"17Department of Transplant and Cellular Therapy, Sarah Cannon Cancer, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspian H.","family":"Oliai","sequence":"additional","affiliation":[{"name":"14Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"18Department of Transplant and Cellular Therapy, Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Luke","family":"Mountjoy","sequence":"additional","affiliation":[{"name":"19Department of Lymphoma, Colorado Blood Cancer Institute, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-8955","authenticated-orcid":false,"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[{"name":"8Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Tsai","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica T.","family":"Leonard","sequence":"additional","affiliation":[{"name":"20Division of Hematology-Oncology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"21Department of Hematology and Oncology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-462X","authenticated-orcid":false,"given":"Joshua P.","family":"Sasine","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Kumaran","sequence":"additional","affiliation":[{"name":"22Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle","family":"Frey","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Koura","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center and University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"23Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"3","key":"2025082609465052900_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.10265","article-title":"Central nervous system relapse in adults with acute lymphoblastic leukemia","volume":"94","author":"Surapaneni","year":"2002","journal-title":"Cancer"},{"issue":"11","key":"2025082609465052900_bib2","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.leukres.2008.04.011","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and\/or at first relapse: results from the GET-LALA group","volume":"32","author":"Reman","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2025082609465052900_bib3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2025082609465052900_bib4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2022017035","article-title":"How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia","volume":"141","author":"Kopmar","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025082609465052900_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"2025082609465052900_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2025082609465052900_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10299","key":"2025082609465052900_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"2025082609465052900_bib9","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials [published correction appears in Lancet Hematol. 2021;8(11):e789]","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025082609465052900_bib10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"issue":"23","key":"2025082609465052900_bib11","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025082609465052900_bib12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.19037","article-title":"Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement","volume":"203","author":"Ryan","year":"2023","journal-title":"Br J Haematol"},{"issue":"22","key":"2025082609465052900_bib13","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","article-title":"Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"35","author":"Winick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025082609465052900_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9967","key":"2025082609465052900_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2025082609465052900_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jtct.2023.10.005","article-title":"INSPIRED Symposium part 4A: access to CAR T cell therapy in unique populations with B cell acute lymphoblastic leukemia","volume":"30","author":"Winestone","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2025082609465052900_bib17","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025082609465052900_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"2025082609465052900_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2022.281110","article-title":"Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy","volume":"108","author":"Berger","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2025082609465052900_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2025082609465052900_bib21","doi-asserted-by":"crossref","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","article-title":"CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern?","volume":"14","author":"Velasco","year":"2023","journal-title":"Front Neurol"},{"key":"2025082609465052900_bib22","doi-asserted-by":"crossref","first-page":"693200","DOI":"10.3389\/fimmu.2021.693200","article-title":"Efficacy and safety of axicabtagene ciloleucel and tisagenlecleucel administration in lymphoma patients with secondary CNS involvement: a systematic review","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"2025082609465052900_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a Pediatric Real World CAR Consortium report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2025082609465052900_bib24","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2025082609465052900_bib25","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"13","key":"2025082609465052900_bib26","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2023012255","article-title":"CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2025082609465052900_bib27","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1182\/bloodadvances.2024013393","article-title":"CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas","volume":"8","author":"Cederquist","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2025082609465052900_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025082609465052900_bib29","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1182\/bloodadvances.2024013962","article-title":"Efficacy and tolerance of brexucabtagene autoleucel in adults with R\/R B-ALL: a GRAALL study from the DESCAR-T registry","volume":"8","author":"Rabian","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2025082609465052900_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41375-019-0570-1","article-title":"Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study","volume":"34","author":"Thastrup","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025082609465052900_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3324\/haematol.2019.231704","article-title":"Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network","volume":"106","author":"Del Principe","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"2025082609465052900_bib32","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/cncr.34073","article-title":"Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia","volume":"128","author":"Garcia","year":"2022","journal-title":"Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4081\/2406474\/blooda_adv-2024-015779-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4081\/2406474\/blooda_adv-2024-015779-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T13:47:04Z","timestamp":1756216024000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4081\/537144\/Outcomes-of-brexucabtagene-autoleucel-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015779","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,13]]}}}